New drug duo aims to supercharge immune attack on head and neck tumors before surgery

NCT ID NCT07455032

Recruiting now Disease control Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated May 12, 2026 · Updated 7 times

Summary

This early-phase trial tests whether adding an experimental skin injection (CADI-05) to standard immunotherapy (pembrolizumab) can help the immune system better fight advanced head and neck cancer before surgery. About 22 adults with resectable, locally advanced disease will receive both treatments for 5 weeks, then undergo surgery. Researchers will monitor side effects and check how much tumor remains after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Temple University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19140, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SQUAMOUS CELL CARCINOMA OF HEAD AND NECK